Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.284 - Eosinophilic Esophagitis Before and After Milk Oral Immunotherapy in Children with Food Allergy: A Case Series Including the Eosinophil-to-Lymphocyte Ratio
D1.283 - Endolysosomal degradation of major peanut allergens revealed distinct degradation kinetics and T cell epitope regions
D1.286 - Allergenic Protein Profiling in a Patient with Long-standing Nut-Induced Anaphylaxis
D1.287 - Polysensitization to Seed Storage Proteins, LTPs and Profilin in a Patient With Anaphylaxis After Consumption of Pesto Sauce
- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests
- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom
- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)
- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center
- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom
- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data
- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy
- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review
- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase
- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy
D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas
- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
Download the app
The congress at your fingertips
Available on
Download